GC CELL CORPORATION
GC Cell develops cell and gene therapies including Immuncell-LC and NK cell therapy pipelines licensed to Artiva Biotherapeutics in the US.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2011 and listed on KOSDAQ in 2016, GC Cell originated from the 2011 acquisition of Green Cross's cell therapy business. It develops the liver cancer treatment Immuncell-LC alongside gene-modified NK cell therapies CAR-NK and CAR-T, and also runs specimen testing, cord blood banking, bio-logistics (G-HUB), and CDMO businesses. It has licensed NK cell therapy programs AB-101, AB-201, AB-202, and AB-205 (GCC2005) to Artiva Biotherapeutics in the US, and in September 2024 completed a technology transfer of Immuncell-LC to PT Bifarma Adiluhung in Indonesia.
Products & technology
- Immuncell-LCLiver cancer (hepatocellular carcinoma) treatment
- NK/T cell therapies (CAR-NK, CAR-T)Next-generation cell therapies; CD5 CAR-NK targets T-cell blood cancers
- Specimen testing serviceSpecimen testing for disease diagnosis, prevention, treatment and health assessment
- Cord blood bank serviceCord blood storage and hematopoietic stem cell services
- Bio-logistics service (G-HUB)Cold chain transport/storage and integrated logistics management for cell therapies, specimens, and pharmaceuticals
- CDMO serviceContract development and manufacturing of pharmaceuticals
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2025 / 1 Korean MFDS drug approvals · 2021
- Orphan자가유래 BCMA 표적 CAR-T 세포치료제2025-07-09Orphan Drug designation20250075015
- MFDS drugImmuncell-LC2021-08-27Drug · Prescription · Approval202106211
Clinical trials
data.go.kr7 MFDS clinical trial authorisations · 2016–2024 (Phase 1 4 · Phase 3 1 · Phase 1/2 1 · Phase 2a 1)
- Phase 1GCC20052024-08-14
3 trial sites
- Phase 1AB-2012023-12-21
- Phase 1CT3032021-10-19
3 trial sites
- Phase 1CT3032021-08-18
3 trial sites
- Phase 3이뮨셀엘씨주2020-12-21
14 trial sites
- Phase 1/2MG41012018-10-02
3 trial sites
- Phase 2aMG41012016-01-11
6 trial sites
R&D and key agreements
Source: DART corporate disclosureCD5 CAR-NK · T세포 혈액암 · 임상승인 · Received clinical trial approval as a treatment for T-cell blood cancers with high unmet need.
AB-101 · NK세포치료제 (항체 병용) · 미국 임상 1/2a상 진행 중 · Combination trial with an antibody is ongoing with Artiva Biotherapeutic in the US.
AB-201 · NK세포치료제 · 미국 임상 IND 승인
AB-202 · NK세포치료제 · 미국 임상 IND 준비 중
AB-205(GCC2005) · NK세포치료제 · 한국 임상 1상 진행 중
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition